首页> 美国卫生研究院文献>Journal of Advanced Research >QbD based approach for optimization of Tenofovir disoproxil fumarate loaded liquid crystal precursor with improved permeability
【2h】

QbD based approach for optimization of Tenofovir disoproxil fumarate loaded liquid crystal precursor with improved permeability

机译:基于QbD的方法用于优化替诺福韦富马酸替诺福韦酯装载的液晶前驱体的优化

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

class="kwd-title">Keywords: Liquid crystal precursor, Glyceryl monooleate, Tenofovir disoproxil fumarate, Quality by design, Permeation flux, Factorial design class="head no_bottom_margin" id="ab010title">AbstractBCS class III drugs suffer from a drawback of low permeability even though they have high aqueous solubility. The objective of current work was to screen the suitability of glyceryl monooleate (GMO)/Pluronic F127 cubic phase liquid crystals precursors for permeation enhancement and in turn the bioavailability of tenofovir disoproxil fumarate (TDF), a BCS class III drug. Spray-drying method was used for preparation of TDF loaded liquid crystal precursors (LCP) consisting of GMO/Pluronic F127 and lactose monohydrate with an ability to in situ transform into stable cubic phases upon hydration. The quality by design (QbD) approach (Factorial design) was used for batch optimization. Spherical TDF loaded LCP as revealed by scanning electron microscopy photographs when hydrated and analyzed by small angle X-ray scattering confirmed formation of cubic phase. Differential scanning calorimetry and X-ray diffraction studies confirmed the molecular dispersion of TDF in polymer matrix and also suggested the conversion of TDF from crystalline to amorphous form. In vitro TDF release from prepared LCP showed controlled drug release over a period of 10 h. Further ex vivo studies revealed permeation enhancing activity of prepared LCP, which was highest when tested in presence of digestive enzyme extract. Thus, formulation of stable liquid crystal powder precursor can serve as an alternative for designing oral delivery system for drugs with low permeability.
机译:<!-fig ft0-> <!-fig @ position =“ anchor” mode =文章f4-> <!-fig mode =“ anchred” f5-> <!-fig / graphic | fig / alternatives / graphic mode =“ anchored” m1-> class =“ kwd-title”>关键字:液晶前体,甘油单油酸酯,替诺福韦二吡呋酯富马酸酯,设计质量,渗透通量,析因设计< h2 class =“ head no_bottom_margin” id =“ ab010title”>摘要 BCS III类药物即使具有较高的水溶性,也存在渗透率低的缺点。当前工作的目的是筛选单油酸甘油酯(GMO)/普流尼克F127立方相液晶前体是否适合渗透性增强,以及替诺福韦二富马酸富马酸替诺福韦(TDF)的生物利用度,这是BCS III类药物。喷雾干燥法用于制备载有TDF的液晶前体(LCP),该液晶前体由GMO / Pluronic F127和乳糖一水合物组成,并能在水合后原位转化为稳定的立方相。设计质量(QbD)方法(框架设计)用于批次优化。水合后,通过扫描电子显微镜照片显示,球形TDF负载LCP,并通过小角度X射线散射分析证实形成了立方相。差示扫描量热法和X射线衍射研究证实了TDF在聚合物基质中的分子分散性,并且还暗示了TDF从结晶形式转变为非晶形式。制备的LCP的体外TDF释放显示了10小时内药物的受控释放。进一步的离体研究表明,所制备的LCP的渗透增强活性,在消化酶提取物存在下测试时最高。因此,稳定的液晶粉末前体的制剂可以用作设计用于低渗透性药物的口服递送系统的替代方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号